<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation of health-related quality of life (HRQL) in patients with a serious life-threatening illness</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation of health-related quality of life (HRQL) in patients with a serious life-threatening illness</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation of health-related quality of life (HRQL) in patients with a serious life-threatening illness</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nan Rothrock, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy H Peterman, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Cella, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert M Arnold, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul J Hesketh, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Although difficult to define, quality of life has an inherent meaning to most people. It is comprised of broad concepts that affect global life satisfaction, including good health, adequate housing, employment, personal and family safety, interpersonal relationships, education, and leisure pursuits. For matters related to health care, quality of life has been applied specifically to those life concerns that are most affected by health or illness, hence the term "health-related quality of life" (HRQL) [<a href="#rid1">1</a>].</p><p>The concept of HRQL emerged from the broader concept of general quality of life, and is, by definition, more focused on aspects of life quality that are influenced by or can influence one's health status directly. These aspects can include symptoms of disease and treatment side effects, treatment satisfaction, physical functioning and wellbeing, social functioning and life satisfaction, and mental health, including emotional wellbeing and cognitive functioning. HRQL does not typically include aspects of life that are often associated with the broader concept of quality of life, such as income, financial resources, nutrition, and environmental conditions such as air quality, climate, political and personal freedoms, and public safety (crime). Some research has begun to look at some of these broader quality of life domains and their relationship with HRQL. Often referred to as the social determinants of health, these concepts outside of the definition of HRQL are outside the scope of this document.</p><p>Specific measures to evaluate the outcome of a serious illness or its treatment include quantity and quality of life, as well as economic cost to the patient (ie, the financial burden of care). Although length of survival has historically been considered the most important among these, the impact of illness on quality of life has received increasing recognition. Since the 1980s, improvement in HRQL has been one of two potential benefits that are considered by the US Food and Drug Administration (FDA) as a basis for full approval of new anticancer drugs [<a href="#rid2">2</a>]. In 2009, the FDA released specific guidance for the development and validation of quality of life measures (also known as patient-reported outcome measures [PROMs]) that could be suitable for regulatory purposes [<a href="#rid3">3</a>]. Further developed by FDA authors in 2016, the recommended quality-of-life components for drug labeling purposes include disease-related symptoms, physical function, and patient-reported adverse events [<a href="#rid4">4</a>]. An ontology for patient-reported outcomes has been published [<a href="#rid5">5</a>].</p><p>Historically, HRQL has been a fundamental concern of oncologic practice since 1949, when Karnofsky and Burchenal developed a clinical scale to quantify the functional performance of cancer patients  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 1</a>) [<a href="#rid6">6,7</a>]. Increasing interest in the systematic assessment of HRQL in cancer patients using standardized, self-administered measures has emerged over the past three decades [<a href="#rid8">8</a>] and has become an important focus of benefit for newer therapies [<a href="#rid9">9-14</a>], as well as a basis for documenting the quality of cancer care [<a href="#rid15">15</a>].</p><p>HRQL is a particularly important issue for patients who are in the advanced stages of a serious life threatening illness. Palliative care is an interdisciplinary medical specialty that focuses on preventing and relieving suffering and on supporting the best possible quality of life for patients and their families facing serious illness. (See  <a class="medical medical_review" href="/z/d/html/14240.html" rel="external">"Benefits, services, and models of subspecialty palliative care"</a>.)</p><p>Here we will discuss assessment of HRQL in patients with serious life-threatening medical illness, emphasizing malignant disease and palliative care patients. Issues specific to HRQL in patients with head and neck cancer and those undergoing hematopoietic cell transplantation are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3369.html" rel="external">"Health-related quality of life in head and neck cancer"</a> and  <a class="medical medical_review" href="/z/d/html/122403.html" rel="external">"Survival, quality of life, and late complications after hematopoietic cell transplantation in adults", section on 'Quality of life'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINING HRQL</span><span class="headingEndMark"> — </span>HRQL can be formally defined as "the extent to which one's usual or expected physical, emotional, and social wellbeing are affected by a medical condition or its treatment" [<a href="#rid16">16</a>]. This definition incorporates the two widely accepted aspects of quality of life: subjectivity and multidimensionality [<a href="#rid17">17</a>].</p><p>HRQL represents a subjective appraisal of the impact of illness or its treatment; individual patients with the same objective health status can report dissimilar HRQL due to unique differences in expectations and coping abilities [<a href="#rid18">18</a>]. As a result, HRQL must be measured from the individual's viewpoint rather than that of outside observers (ie, caregivers or health care professionals) whenever possible. The importance of obtaining HRQL reports from patients, themselves, is highlighted by a substantial literature documenting disparate estimates of symptoms and HRQL between patients and their physicians [<a href="#rid19">19</a>].</p><p>Multidimensionality is the other important component of HRQL. The multidimensionality of HRQL is reflected in the work of the Patient-Reported Outcomes Measurement Information System (PROMIS), a National Institutes of Health (NIH)-funded national effort that has produced a comprehensive, conceptual framework of self-reported health for adults  (<a class="graphic graphic_table graphicRef98059" href="/z/d/graphic/98059.html" rel="external">table 2</a>) and children  (<a class="graphic graphic_table graphicRef98060" href="/z/d/graphic/98060.html" rel="external">table 3</a>) [<a href="#rid20">20-22</a>]. Developed with the input of thousands of people with a wide variety of medical conditions, the health care providers who treat them, members of the general population, and extensive literature reviews, the framework is divided into physical, mental, and social health. Each of these major components encompasses multiple subcomponents (eg, the mental health component for adults is comprised of anxiety, depression, anger, positive affect, life satisfaction, meaning and purpose, cognitive function, experience of stress, self-efficacy, smoking, substance use, and psychosocial impact of illness).</p><p>An important point is that serious and life-threatening illness can also result in positive outcomes [<a href="#rid23">23,24</a>] such as emotional and spiritual growth, greater closeness with family and friends, and an appreciation of one's inner strength. These psychosocial benefits are included in the Psychosocial Illness Impact – Positive domain of PROMIS [<a href="#rid25">25</a>].</p><p>The utility of PROMIS for patient-reported outcomes is discussed further below. (See <a class="local">'Combined instruments for patient-reported outcomes'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">MEASURING HRQL</span><span class="headingEndMark"> — </span>A vast array of validated and reliable questionnaires are available for assessment of HRQL [<a href="#rid26">26</a>]. They include generic health status instruments, generic illness instruments, and targeted instruments. HRQL instruments comprise the majority of patient-reported outcome measures (PROMs).</p><p class="headingAnchor" id="H4"><span class="h2">Generic health status</span><span class="headingEndMark"> — </span>Generic health status questionnaires are applicable to all populations and can be completed by individuals both with and without medical illness. These instruments provide benchmarks for comparison across diverse groups, such as healthy and ill populations or different age groups. Examples include the Nottingham Health Profile (NHP) [<a href="#rid27">27</a>] and the Short Form-36 (SF-36) from the Medical Outcomes Study [<a href="#rid28">28,29</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Generic illness</span><span class="headingEndMark"> — </span>Generic illness instruments are applicable to populations with any medical illness or condition and can be used to compare different illnesses, levels of disease severity, or types of interventions. Such cross-disease comparisons are increasingly important in the allocation of limited health care resources [<a href="#rid30">30</a>]. In addition to measuring general health status, these instruments typically assess the individual's perception of the functional impact of the illness or disability. Examples include the Sickness Impact Profile (SIP) [<a href="#rid31">31</a>] and the Functional Assessment of Chronic Illness Therapy (FACIT) [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Targeted</span><span class="headingEndMark"> — </span>Targeted instruments, often referred to as disease- or condition-specific measures, are designed to assess the HRQL of individuals with specific illnesses (eg, cancer, heart disease, diabetes), specific types of treatment (eg, chemotherapy, lung transplant, palliative care), or symptoms that are specific to some, but not all, conditions (eg, nausea, urinary incontinence). Compared with other types of instruments, these measures provide a more detailed assessment for specific contexts and are also likely to be more sensitive to specific treatment-related changes in HRQL. Examples include the Diabetes Quality of Life instrument (DQOL) [<a href="#rid33">33</a>], the Functional Living Index - Cancer (FLIC) [<a href="#rid34">34</a>], the Functional Assessment of Cancer Therapy-General-7 (FACT-G7), and the European Organization for Research and Treatment of Cancer Quality of Life Core 15-Palliative Care (EORTC QLQ-C15-PAL) [<a href="#rid35">35-38</a>].</p><p>One trend in HRQL research is to combine generic and disease-specific instruments in order to fully cover important areas that may impact on HRQL. This has been the standard practice of the FACIT Measurement System [<a href="#rid39">39</a>]. Using the Patient-Reported Outcomes Measurement Information System (PROMIS), for example, universal items assessing physical, mental, and social health were combined with heart failure-specific items to create a comprehensive tool for use in research and patient care [<a href="#rid40">40</a>]. A similar approach has been utilized for patients with osteoarthritis of the knee [<a href="#rid41">41</a>] and sickle cell disease [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Combined instruments for patient-reported outcomes</span></p><p class="headingAnchor" id="H8"><span class="h3">PROMIS</span><span class="headingEndMark"> — </span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.healthmeasures.net%2Fexplore-measurement-systems%2Fpromis&amp;token=hDyBhXQdVk422gHHSs8VgcMirSi%2FAAkIbVymhHxkfKZby%2B9ZTVxrYZNmduDeJZLBowWJB30hEo6Ypv2cuqhQb2QJx%2FnYGS0ly6g1GezFdKQ%3D&amp;TOPIC_ID=2833" target="_blank">PROMIS</a> [<a href="#rid20">20,21</a>] presents a set of multidimensional HRQL instruments that combine features of the three categories above  (<a class="graphic graphic_table graphicRef98059" href="/z/d/graphic/98059.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef98060" href="/z/d/graphic/98060.html" rel="external">table 3</a>). PROMIS instruments are applicable across chronic illness populations [<a href="#rid43">43,44</a>]. Item banks for computer adaptive testing and short forms exist for physical function, upper extremity function, pain interference, pain behavior, pain intensity, pain quality, fatigue, sleep disturbance, sleep-related impairment, gastrointestinal symptoms, dyspnea, itch, sexual function and satisfaction, depression, anxiety, anger, alcohol use, smoking, substance use, psychosocial impact of illness, positive affect, life satisfaction, meaning and purpose, cognitive function, self-efficacy for managing chronic conditions, ability to participate in social roles and activities, satisfaction with participation in social roles and activities, companionship, emotional support, informational support, instrumental support, isolation, and global health in adults.</p><p>In addition, there are pediatric instruments for physical function (upper extremity, mobility), pain interference, pain intensity, pain behavior, pain quality, fatigue, physical activity, physical stress experience, strength impact, sleep, depressive symptoms, anxiety, anger/irritability, cognitive function, engagement, life satisfaction, meaning and purpose, positive affect, psychological stress experiences, peer relationships, family relationships, social relationships, asthma impact, and global health. Measures can be completed by self-report beginning at age 8 [<a href="#rid45">45</a>] or by a parent reporting on behalf of a child ages 1 to 17 [<a href="#rid22">22,46</a>].</p><p>All of the PROMIS instruments were developed using rigorous qualitative [<a href="#rid47">47-49</a>] and quantitative [<a href="#rid21">21,50-52</a>] methods, including use of item response theory, an analytic strategy that allows for the creation of customized short forms and use of a common metric [<a href="#rid53">53</a>]. Although PROMIS instruments have had limited application in palliative care populations [<a href="#rid54">54-57</a>], the breadth of domain coverage suggests utility for research and clinical care in this population as well. This is supported by work demonstrating PROMIS measures predicting survival in patients receiving palliative care [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Neuro-QoL</span><span class="headingEndMark"> — </span>The Quality of Life in Neurological Disorders project (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.healthmeasures.net%2Fexplore-measurement-systems%2Fneuro-qol&amp;token=pFULaKERUBccKD%2BGOGd9Hl9VMXKA2XawtN2WSPy1Jc1nUNQxJcJ5MqWy03q00ntbyZ3eFTr70iQG7LdegVD31UBLPK2ou%2BUIgOf6lHTFhsw%3D&amp;TOPIC_ID=2833" target="_blank">Neuro-QoL</a>), conceptually and methodologically similar to PROMIS, was funded by the National Institute of Neurological Disorders and Stroke to develop and test HRQL instruments that are applicable across the many neurologic conditions. These instruments were initially developed and validated in five adult and two pediatric diseases (stroke, amyotrophic lateral sclerosis [ALS], multiple sclerosis, Parkinson disease, adult and pediatric epilepsy, and the muscular dystrophies) [<a href="#rid59">59-61</a>]. Parallel work extended Neuro-QoL to people with spinal cord injury (SCI-QoL) [<a href="#rid62">62</a>], traumatic brain injury (TBI-QoL) [<a href="#rid63">63</a>], Huntington disease [<a href="#rid64">64</a>], and caregivers for individuals with traumatic brain injuries [<a href="#rid65">65</a>]. The resulting HRQL tools are used in clinical trials [<a href="#rid66">66</a>] and comparative effectiveness research [<a href="#rid67">67</a>]. The common metrics of Neuro-QoL facilitates the comparison of results from clinical trials and other clinical research across conditions.</p><p class="headingAnchor" id="H10"><span class="h2">Proxy or caregiver evaluations of HRQL</span><span class="headingEndMark"> — </span>There are situations (eg, children, older adults, cognitively impaired patients, end-of-life care settings with a very ill patient) where patient self-reported HRQL must be substituted by proxy assessment. Where it has been studied, there appears to be general agreement between the patient's assessment and that of family caregiver proxies in most [<a href="#rid68">68-73</a>] but not all [<a href="#rid74">74</a>] studies. Also, the possibility of bias related to the subjective burden of caring for the individual must be considered when the proxy is a caregiver [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/z/d/html/86248.html" rel="external">"Advance care planning and advance directives", section on 'Surrogate decision-makers'</a>.)</p><p>Relatedly, it is also important to consider the quality of life of the family members of people with serious illness. Partners, children, and parents can experience significant alterations in their emotional, social, and even physical wellbeing in response to the illness of a loved one [<a href="#rid76">76,77</a>].</p><p class="headingAnchor" id="H11"><span class="h1">UTILIZATION OF HRQL DATA</span><span class="headingEndMark"> — </span>Information regarding the impact of an illness or medical condition on HRQL can be put to use in several ways.</p><p class="headingAnchor" id="H12"><span class="h2">Clinical trials</span><span class="headingEndMark"> — </span>Clinical trials that compare two (or more) treatments often include a HRQL assessment and analysis to help determine overall clinical benefit, particularly when treatment-related side effects are considerable. Compared with the control therapy, the alternative treatment option may be associated with a variety of combinations of relative survival benefit and HRQL. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Longer survival with better HRQL</p><p class="bulletIndent1"><span class="glyph">●</span>Similar survival but better HRQL</p><p class="bulletIndent1"><span class="glyph">●</span>Shorter survival but better HRQL</p><p class="bulletIndent1"><span class="glyph">●</span>Longer survival but with inferior HRQL</p><p class="bulletIndent1"><span class="glyph">●</span>Shorter survival with an inferior HRQL</p><p></p><p>Although no individual would purposely select a treatment that results in both shorter survival and a worse HRQL, improved HRQL during therapy may be perceived as sufficiently compelling (particularly during cancer treatment) to outweigh a somewhat shorter survival duration.</p><p>Improvement in HRQL as an endpoint in clinical research requires recruitment of sufficient numbers of subjects for a trial to have adequate power. Instruments measuring HRQL with a limited coefficient of variation can decrease the size of a trial needed and offer an important advantage in this regard [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Routine collection of HRQL in clinical care</span><span class="headingEndMark"> — </span>Because HRQL information can provide a detailed assessment of disease and treatment effects, and their global impact on the individual's daily life, routine HRQL assessment with patient-reported outcome measures (PROMs) is increasingly integrated into clinical practice. In this setting, PROMs can serve multiple purposes such as screening for depression or anxiety, monitoring symptoms or outcomes [<a href="#rid79">79,80</a>]. They can also facilitate symptom management and detection of unrecognized problems. For instance, a brief multidimensional HRQL instrument might be administered at every chemotherapy visit. The treating nurse or clinician can then review the current HRQL for indications of problems and compare it with the HRQL from the previous visit. Significant changes can be flagged for follow-up by a provider. A quick glance at a standardized computer-generated printout of HRQL scores and changes from the last visit's scores could catch a problem that might otherwise be missed.</p><p>Routine collection of HRQL using PROMs has been shown to be feasible and acceptable to patients and staff and has demonstrated multiple benefits, including improved patient-provider communication, increased patient satisfaction, detection of unrecognized problems, increased actions by clinicians, reduced emergency department admissions and hospitalizations, improved HRQL, and, in two studies, increased survival [<a href="#rid81">81-92</a>]. Several health centers have implemented PROMs across conditions and technologies [<a href="#rid91">91-95</a>].</p><p>A systematic review of PROMs data from 16 studies in palliative care, mostly randomized controlled trials with oncology patients, concluded that PROMs improved some care processes (eg, patient-provider communication about symptoms) and some outcomes, including patient and caregiver psychological wellbeing [<a href="#rid82">82</a>]. However, the evidence for an effect on overall HRQL and symptom burden was mixed.</p><p>A growing literature identifies the enablers and barriers to implementing HRQL assessment in routine clinical practice [<a href="#rid96">96-102</a>]. Professional organizations (eg, ISOQOL [<a href="#rid103">103</a>], NQF [<a href="#rid104">104</a>], <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ftheproteusconsortium.org%2Fabout%2F&amp;token=VQ6wknPko%2FVQ1iR9ZD8nNw3cZamLKN2h6MAX1cKrpavG9BKjQKkvHC%2FZyKRzjM7N&amp;TOPIC_ID=2833" target="_blank">PROTEUS Consortium</a>) and implementation grants (eg, ePROs in Clinical Care [<a href="#rid105">105</a>], <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.healthmeasures.net%2F&amp;token=sL%2Bp%2BgWoM5K8OZ3TcR7z2fkBhGNMO9hu6Rk7kPK4maCLIak7z6ioHobajiRkpIFZ&amp;TOPIC_ID=2833" target="_blank">HealthMeasures</a>) have generated practical tools.</p><p class="headingAnchor" id="H15"><span class="h2">Predicting treatment response</span><span class="headingEndMark"> — </span>HRQL data can also be used to predict the outcome of treatment. As an example, in patients with metastatic lung cancer, pretreatment HRQL predicted the likelihood of an objective response to chemotherapy treatment, and the change in HRQL between baseline and six weeks after treatment initiation also predicted survival [<a href="#rid106">106,107</a>] (see  <a class="medical medical_review" href="/z/d/html/4629.html" rel="external">"Subsequent line therapy in non-small cell lung cancer lacking a driver mutation"</a>). The importance of this type of information for stratification of patients during random treatment assignment is obvious [<a href="#rid108">108</a>]. This also facilitates the creation of shared decision-making tools when a patient is considering different treatment options [<a href="#rid109">109</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Treatment decision-making in advanced life-threatening illness</span><span class="headingEndMark"> — </span>Prolongation of life, without regard for the quality of that life, is not a universally desired goal. When considering aggressive, life-prolonging treatments and end-of-life decisions, it is necessary to consider each individual's assessment of what makes life worth living. (See  <a class="medical medical_review" href="/z/d/html/2197.html" rel="external">"Overview of comprehensive patient assessment in palliative care", section on 'Illness understanding and care preferences'</a> and  <a class="medical medical_review" href="/z/d/html/2197.html" rel="external">"Overview of comprehensive patient assessment in palliative care", section on 'Religious, spiritual, and existential (transcendent) issues'</a>.)</p><p>Some patients are willing to consider aggressive and potentially toxic treatments despite slim chances of survival; medical issues do not always constitute the main factors considered. In one series, aggressive therapy was more likely to be accepted among patients with a positive sense of social wellbeing or children living at home [<a href="#rid110">110</a>]. In a second report, 388 older adults were presented with 17 hypothetical decision situations depicting terminal and nonterminal conditions with a very low quality of life and asked to rank the acceptability of several end-of-life options [<a href="#rid111">111</a>]. The majority chose striving to live and seeking active treatment over death, even if they had a poor HRQL characterized by pain, immobility, and extreme dependence on others. Psychosocial variables, including religiosity, values, and fear of death, contributed significantly to the decision-making process, highlighting the complex relationship between HRQL and quality of life. (See <a class="local">'The influence of nonmedical issues'</a> below.)</p><p>For patients with a serious, life-threatening illness, the decision to continue potentially life-lengthening treatment is obviously a very individual one. However, what is also clear is that appropriate palliative care can improve HRQL by reducing symptom burden and decreasing interference with usual life activities. (See  <a class="medical medical_review" href="/z/d/html/14240.html" rel="external">"Benefits, services, and models of subspecialty palliative care"</a> and  <a class="medical medical_review" href="/z/d/html/2199.html" rel="external">"Overview of managing common non-pain symptoms in palliative care"</a>.)</p><p>A National Institutes of Health (NIH)-sponsored cooperative research group was founded in 2010 to study treatment-related issues that are specific to the setting of palliative and end of life care [<a href="#rid112">112,113</a>]. The Palliative Care Research Cooperative Group supports clinical trials and other relevant research. For example, one study demonstrated that cessation of statin therapy in terminally ill patients is safe and may improve quality of life and reduce cost [<a href="#rid114">114</a>]. (See  <a class="medical medical_review" href="/z/d/html/14241.html" rel="external">"Palliative care: The last hours and days of life", section on 'Eliminating non-essential medications'</a>.)</p><p>In addition, the measurement core of this group maintains a published library of recommended instruments to measure patient-reported outcomes and quality indicators in palliative care [<a href="#rid115">115</a>].</p><p class="headingAnchor" id="H3103517908"><span class="h2">Evaluation of quality of health care</span><span class="headingEndMark"> — </span>The evaluation of health care quality has largely utilized measures that assess the process of care. These performance measures can include assessments, such as the proportion of providers that conduct a foot examination in diabetic patients, or recommend or prescribe an indicated treatment for a specific condition. Increasingly, payers and providers are interested in additionally utilizing HRQL measures that capture outcomes of care. Patient-reported outcome performance measures (PRO-PMs) include assessments such as the level of patient-reported depressive symptoms, degree of physical function, pain, and sleep quality. Guidance for the development, evaluation, and maintenance of performance measures generally [<a href="#rid116">116,117</a>], and PRO-PMs specifically [<a href="#rid118">118,119</a>], has been published. The methodological issues related to the selection, administration, and use of PRO-PMs, including generic versus disease-specific PROs, process (eg, assessment of depressive symptoms) versus outcome (eg, level of depressive symptoms) measures, and risk adjustment, are beginning to be better understood [<a href="#rid15">15,118-120</a>].</p><p class="headingAnchor" id="H17"><span class="h1">CHALLENGES IN HRQL RESEARCH</span><span class="headingEndMark"> — </span>Despite the progress in HRQL research over the last four decades, several challenges remain. These include the identification of what constitutes clinically significant differences and meaningful changes in HRQL, the development and testing of conceptual models linking medical and psychological variables to HRQL [<a href="#rid121">121</a>], and the validation of existing item banks and computer adaptive tests as measures of HRQL that enable comparison across diseases and treatments.</p><p class="headingAnchor" id="H18"><span class="h2">Defining a clinically meaningful change</span><span class="headingEndMark"> — </span>What degree of change in HRQL is of sufficient magnitude to warrant a treatment modification by the clinician? Identifying changes in HRQL that are clinically significant involves determining whether the change that is observed in response to an intervention is meaningful and important, or statistically significant yet clinically irrelevant [<a href="#rid122">122-124</a>].</p><p>For patients with progressive conditions, such as many of the neurologic disorders, even stable scores can be clinically meaningful, since they can indicate the avoidance of decline or loss of function. For example, maintaining the ability to move a finger can mean that an individual can operate an electric wheelchair, while maintaining the ability to swallow means that an individual can still eat and drink [<a href="#rid125">125</a>]. This highlights the significance of incorporating patient and caregiver input, utilizing instruments that are sensitive to very small score changes, and prospectively defining clinically meaningful outcomes in both research and practice.</p><p>One approach to answering this question is to compare changes in HRQL scores with global ratings of change in different life dimensions [<a href="#rid126">126</a>] or in life stress units [<a href="#rid18">18</a>]. As an example, in one report, an important difference (ID) was defined based on patients' global ratings of change and applied to three studies measuring dyspnea, fatigue, and emotional function in patients with chronic heart and lung disease [<a href="#rid126">126</a>]. The ID was represented by a mean change in score of approximately 0.5 per item on the HRQL instrument, when responses were presented on a 7-point Likert scale.</p><p>Complementary approaches to this question have received considerable attention. For example, clinically important differences or changes can be calculated by comparison of HRQL score differences or changes to parallel differences or changes in meaningful anchors, such as the patient's global rating of change mentioned above or clinical measures relevant to a given condition (such as tumor response in oncology or hemoglobin change in anemic patients). Other important HRQL anchors used in oncology, for example, include disease stage/severity, treatment status, progression-free survival, and performance status.</p><p>Distribution-based methods calculate an ID by applying a criterion of one-third to one-half of the pooled standard deviation, or, alternatively, the standard error of measurement, of the measure at the baseline assessment. Results from several studies indicate that similar estimates are obtained regardless of the method used [<a href="#rid127">127-129</a>]. In part because of this, the widespread use of a standard deviation to define meaningful group differences across HRQL measures has been popular [<a href="#rid130">130</a>]. Although this may be useful as a starting point for clinicians who are not familiar with particular HRQL measures, more credible estimates can be obtained through the use of anchors that are sufficiently correlated with the target HRQL measure. Indeed, multiple methods for deriving a range of recommended IDs may be most appropriate [<a href="#rid131">131,132</a>].</p><p>Another approach to aid in clinical interpretation of HRQL scores has been to identify meaningful cut-points (eg, the threshold at which time a clinician may consider a referral for emotional distress or modification of pain medication) [<a href="#rid133">133</a>]. The successful establishment of meaningful cut-scores for symptoms (eg, mild, moderate, or severe) has been demonstrated in cancer patients [<a href="#rid134">134,135</a>], patients with serious neurologic conditions [<a href="#rid136">136</a>], patients with rheumatic disease [<a href="#rid137">137,138</a>], patients with spinal cord injury [<a href="#rid139">139</a>], and pediatric patients with juvenile idiopathic arthritis [<a href="#rid140">140</a>]. Unlike IDs, this approach recognizes that a change in score may have different meanings depending on where in the range of scores it takes place. For example, the meaningfulness of a decrease in pain is dependent on the baseline pain level, with a larger decrease required for meaningfulness with a higher starting pain level [<a href="#rid141">141</a>] in pain scores is required for meaningful change.</p><p>To summarize, evaluating the clinical meaningfulness of a HRQL score or change has great significance for patients, clinicians, payers, and regulators. Recommendations suggest that more appropriate and precise definitions can be obtained through a triangulation of multiple approaches, such as those outlined above, and sophisticated analytic strategies [<a href="#rid142">142</a>].</p><p class="headingAnchor" id="H709047002"><span class="h3">Palliative care patients</span><span class="headingEndMark"> — </span>Defining a clinically meaningful change can be particularly challenging for palliative care patients. People living with chronic, life-threatening illness often progress through specific phases of clinical worsening and increasing physical, mental, and social challenges. Furthermore, when people are severely ill or disabled, it can be difficult to simply obtain reliable responses to a long set of questions. For this reason, many have abbreviated questionnaires for use in end-of-life studies [<a href="#rid36">36</a>].</p><p>However, disease progression is often accompanied by a shift in priorities or life goals of the patient and family [<a href="#rid16">16,143</a>]. When this happens, it can have an effect on responses to self-report questionnaires about symptoms and functional abilities. Often, social, family, and spiritual issues become more important than they were previously. In fact, this sometimes results in the counterintuitive finding that overall quality of life is maintained, or even improved, even in the face of worsening physical symptoms and functioning [<a href="#rid144">144</a>].</p><p>There are suggestions for measuring these emerging issues and how they might modify the value people place on what is clinically meaningful. For example, specific questions can be added to existing measurements such as the Functional Assessment of Cancer Therapy (FACT) and Functional Assessment of Chronic Illness Therapy (FACIT) [<a href="#rid145">145-147</a>]. Another instrument, the Quality of Life at the End of Life instrument (QUAL-E), includes the domains of life completion and preparation for the end of life [<a href="#rid148">148</a>].</p><p>In addition, there have been many efforts to individualize HRQL to the individual, including tailoring the questions that are asked, weighting individual questions or domains for their relative importance to the patient, or allowing patients to select their most important concerns and tracking them over time. Unfortunately, this has proven difficult to implement; limited investigations suggest that weighting has little additional predictive value [<a href="#rid149">149</a>], and there are legitimate concerns about comparing one person's individualized score with that of another. Nonetheless, several such individualized instruments are available, including the Patient-Generated Index [<a href="#rid150">150</a>] and the Schedule for the Evaluation of Individual Quality of Life [<a href="#rid151">151</a>].</p><p class="headingAnchor" id="H19"><span class="h2">The influence of nonmedical issues</span><span class="headingEndMark"> — </span>A second challenge is to develop and test models of non-illness-related factors (eg, psychological, social, cultural, and economic issues) that might influence the impact of a particular level of impairment on HRQL. In one model, the amount of distress and dissatisfaction experienced by the patient as a result of the symptoms and functional limitations induced by illness and its treatment is influenced by individual factors, sociocultural influences, and available resources [<a href="#rid108">108</a>]. Other proposed models relate physiological variables, symptoms report, and physical functioning to overall HRQL [<a href="#rid152">152</a>]. Evaluation of these interrelationships is critical to an understanding of what influences HRQL and the potential for modifying these factors through targeted interventions.</p><p class="headingAnchor" id="H150190047"><span class="h3">Language and culture</span><span class="headingEndMark"> — </span>The nature of self-reported symptoms, function, and quality of life is such that perspectives and reporting are influenced by language and culture. Therefore, it is important when developing questions that their meaning is comparable across different languages and cultures. This is best accomplished through thoughtful writing of concepts so that they are easily translated, and then use of a translation methodology that checks and evaluates cross-cultural relevance and understandability. In some cases, simultaneous development of multiple language versions has been found to be an effective way of increasing comparability across languages and cultural groups. When multiple language versions are used in one study, if sample size permits, evaluation of the performance of each item relative to the others, language-by-language, can also be done. This is referred to as checking for differential item functioning (DIF) by language or cultural group. (See  <a class="medical medical_review" href="/z/d/html/86305.html" rel="external">"Cultural aspects of palliative care"</a>.)</p><p class="headingAnchor" id="H150190067"><span class="h2">Personality and individual differences</span><span class="headingEndMark"> — </span>Psychological characteristics such as optimism/pessimism, neuroticism, depression, and social desirability can influence the overall "tone" of an individual's response to questions. Typically, this is managed as a constant, underlying variable that is generally controlled within-person in a longitudinal change score, and balanced across groups when respondents are randomly assigned. Nevertheless, caution regarding personality influences on reporting is warranted.</p><p class="headingAnchor" id="H696452872"><span class="h2">Spiritual and existential wellbeing</span><span class="headingEndMark"> — </span>Spiritual wellbeing has been defined as a sense of meaning, peace, and connectedness with something larger than oneself [<a href="#rid146">146</a>]. In the face of life-threatening illness, spirituality is often seen as a particularly effective resource for coping with physical symptoms and functional limitations. Conversely, spiritual distress or conflict can be particularly problematic, especially if it is prolonged. With a patient's agreement, chaplains, religious leaders, or spiritually attuned health care providers of many types can assist the patient in exploring sources of distress and resolution. (See  <a class="medical medical_review" href="/z/d/html/2198.html" rel="external">"Overview of spirituality in palliative care"</a> and  <a class="medical medical_review" href="/z/d/html/94167.html" rel="external">"Influence of spirituality and religiousness on outcomes in palliative care patients"</a>.)</p><p>Existential distress ("Why me?", "What does my life mean if it might end soon?") can negatively affect HRQL to an extent similar to physical symptoms, such as pain. Some HRQL assessments, notably the McGill Quality of Life Questionnaire [<a href="#rid153">153</a>] (and its revised version [<a href="#rid154">154</a>]), include an existential wellbeing subscale. As an example, respondents rate whether they have been able to achieve their goals, whether life is worthwhile, and the extent to which every day feels like a burden or a gift. Also, at least one investigator has begun to document the positive effect of an intervention called "meaning-centered psychotherapy" specifically to address the existential questions and distress that can be wrought by a fatal illness [<a href="#rid155">155,156</a>]. (See  <a class="medical medical_review" href="/z/d/html/2197.html" rel="external">"Overview of comprehensive patient assessment in palliative care", section on 'Religious, spiritual, and existential (transcendent) issues'</a> and  <a class="medical medical_review" href="/z/d/html/2198.html" rel="external">"Overview of spirituality in palliative care"</a> and  <a class="medical medical_review" href="/z/d/html/2195.html" rel="external">"Psychosocial issues in advanced illness", section on 'Common issues for patients with advanced illness'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">HRQL and psychology</span><span class="headingEndMark"> — </span>Despite the importance of HRQL research to health and the delivery of medical care, its value is not widely appreciated or recognized within the field of psychology. Fewer relevant publications appear within the psychology literature, despite the rapid growth of the field over the last 20 years. One possibility is that the focus on HRQL as an outcome indicator for medical illness and its treatment has forced the publication of pertinent studies in the medical rather than psychology literature.</p><p>Additionally, the field of psychology has made valuable contributions to the field of HRQL research. The development of valid and reliable instruments to measure the patients' perspective of their illness and treatment was made possible by the demonstration of their psychometric properties; this is largely the work of psychologists. There are now published clinical trials examining the impact of psychologic and/or pharmacologic treatment on various psychiatric diagnoses, including schizophrenia [<a href="#rid157">157,158</a>], major depression [<a href="#rid159">159,160</a>], bipolar disorder [<a href="#rid161">161</a>], and posttraumatic stress disorder [<a href="#rid162">162</a>]. In addition, significant attention is being paid to routine monitoring of patient outcomes as a tool to improve psychotherapy effectiveness [<a href="#rid163">163-165</a>]. With the increasing emphasis on the evaluation of HRQL among populations with mental illness [<a href="#rid152">152,166-168</a>], it appears likely that the next decade will witness a growing recognition of HRQL research by psychology, as the past decade has shown its growth within medicine and health care in general.</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Context</strong> – Quality of life is comprised of broad concepts that affect one's overall life satisfaction. For matters related to health, quality of life has been applied specifically to those life concerns that are most affected by health, illness, or treatment. The term "health-related quality of life" (HRQL) is used for this purpose. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – A definition of HRQL is "the extent to which one's usual or expected physical, emotional, and social wellbeing are affected by a medical condition or its treatment." This definition incorporates the two widely accepted aspects of quality of life: subjectivity and multidimensionality. (See <a class="local">'Defining HRQL'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measurement</strong> – A vast array of validated and reliable questionnaires or patient-reported outcome measures (PROMs) are available for assessment of HRQL in patients with a serious life-threatening illness, including generic health status instruments, generic illness instruments, disease-specific instruments, and combined instruments such as the Patient-Reported Outcomes Measurement Information System (PROMIS)  (<a class="graphic graphic_table graphicRef98059" href="/z/d/graphic/98059.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef98060" href="/z/d/graphic/98060.html" rel="external">table 3</a>). (See <a class="local">'PROMIS'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Application</strong> – There are several areas where HRQL information is of value in medical care; examples are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical trials – Improvement in HRQL as an endpoint in clinical research. (See <a class="local">'Clinical trials'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical care:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>As a tool for assessing the efficacy and tolerability of treatment, capturing changes in clinical status during treatment that might otherwise be missed, and evaluating the need for further assessment, treatment, rehabilitation, or palliative care. (See <a class="local">'Routine collection of HRQL in clinical care'</a> above and <a class="local">'Predicting treatment response'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>As an aid to decision-making in patients who are faced with aggressive, life-prolonging treatments and end-of-life decisions. (See <a class="local">'Treatment decision-making in advanced life-threatening illness'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>As a means of documenting quality of care based on improvement or maintenance of patient-reported outcomes. (See <a class="local">'Evaluation of quality of health care'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bergner M. Quality of life, health status, and clinical research. Med Care 1989; 27:S148.</a></li><li><a class="nounderline abstract_t">Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 1985; 69:1155.</a></li><li class="breakAll">Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims [PDF on the Internet]. Silver Spring (MD). U.S. Food and Drug Administration; 2009. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. (Accessed on May 15, 2019).</li><li><a class="nounderline abstract_t">Kluetz PG, Slagle A, Papadopoulos EJ, et al. Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms. Clin Cancer Res 2016; 22:1553.</a></li><li><a class="nounderline abstract_t">Cella D, Hays RD. A Patient Reported Outcome Ontology: Conceptual Issues and Challenges Addressed by the Patient-Reported Outcomes Measurement Information System® (PROMIS®). Patient Relat Outcome Meas 2022; 13:189.</a></li><li class="breakAll">Karnofsky DA, Burchenal JH. Evaluation of Chemotherapeutic Agents, Macleod CM (Ed), Columbia University Press, New York 1949.</li><li><a class="nounderline abstract_t">Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984; 2:187.</a></li><li><a class="nounderline abstract_t">Cella D, Wagner L, Cashy J, et al. Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy. J Natl Cancer Inst Monogr 2007; :53.</a></li><li><a class="nounderline abstract_t">Cella D, Wagner L. Re-personalizing precision medicine: Is there a role for patient-reported outcomes? J Community Support Oncol 2015; 13:275.</a></li><li><a class="nounderline abstract_t">Cella D, Grünwald V, Escudier B, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol 2019; 20:297.</a></li><li><a class="nounderline abstract_t">Cella D, McKendrick J, Kudlac A, et al. Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Ann Hematol 2018; 97:2455.</a></li><li><a class="nounderline abstract_t">Saad F, Cella D, Basch E, et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19:1404.</a></li><li><a class="nounderline abstract_t">Copeland LJ, Brady MF, Burger RA, et al. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. J Clin Oncol 2022; 40:4119.</a></li><li><a class="nounderline abstract_t">Motzer R, Porta C, Alekseev B, et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol 2022; 23:768.</a></li><li><a class="nounderline abstract_t">Basch E, Snyder C, McNiff K, et al. Patient-reported outcome performance measures in oncology. J Oncol Pract 2014; 10:209.</a></li><li><a class="nounderline abstract_t">Cella DF. Measuring quality of life in palliative care. Semin Oncol 1995; 22:73.</a></li><li><a class="nounderline abstract_t">Aaronson NK. Quality of life: what is it? How should it be measured? Oncology (Williston Park) 1988; 2:69.</a></li><li><a class="nounderline abstract_t">Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334:835.</a></li><li><a class="nounderline abstract_t">Sonn GA, Sadetsky N, Presti JC, Litwin MS. Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol 2009; 182:2296.</a></li><li><a class="nounderline abstract_t">Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007; 45:S3.</a></li><li><a class="nounderline abstract_t">Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 2010; 63:1179.</a></li><li><a class="nounderline abstract_t">Cella D, Blackwell CK, Wakschlag LS. Bringing PROMIS to Early Childhood: Introduction and Qualitative Methods for the Development of Early Childhood Parent Report Instruments. J Pediatr Psychol 2022; 47:500.</a></li><li><a class="nounderline abstract_t">Tedeschi RG, Calhoun LG. The Posttraumatic Growth Inventory: measuring the positive legacy of trauma. J Trauma Stress 1996; 9:455.</a></li><li><a class="nounderline abstract_t">Park CL. Making sense of the meaning literature: an integrative review of meaning making and its effects on adjustment to stressful life events. Psychol Bull 2010; 136:257.</a></li><li><a class="nounderline abstract_t">Lai JS, Garcia SF, Salsman JM, et al. The psychosocial impact of cancer: evidence in support of independent general positive and negative components. Qual Life Res 2012; 21:195.</a></li><li><a class="nounderline abstract_t">Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol 2006; 24:1459.</a></li><li><a class="nounderline abstract_t">Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985; 35:185.</a></li><li><a class="nounderline abstract_t">Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473.</a></li><li><a class="nounderline abstract_t">Reeve BB, Potosky AL, Smith AW, et al. Impact of cancer on health-related quality of life of older Americans. J Natl Cancer Inst 2009; 101:860.</a></li><li><a class="nounderline abstract_t">Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27:S217.</a></li><li><a class="nounderline abstract_t">Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19:787.</a></li><li class="breakAll">Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales, Evanston Northwestern Healthcare, Evanston 1997.</li><li><a class="nounderline abstract_t">Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). The DCCT Research Group. Diabetes Care 1988; 11:725.</a></li><li><a class="nounderline abstract_t">Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984; 2:472.</a></li><li><a class="nounderline abstract_t">Chiu L, Chiu N, Chow E, et al. Comparison of three shortened questionnaires for assessment of quality of life in advanced cancer. J Palliat Med 2014; 17:918.</a></li><li><a class="nounderline abstract_t">Yanez B, Pearman T, Lis CG, et al. The FACT-G7: a rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research. Ann Oncol 2013; 24:1073.</a></li><li><a class="nounderline abstract_t">Groenvold M, Petersen MA, Aaronson NK, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 2006; 42:55.</a></li><li><a class="nounderline abstract_t">Nunes NA. The quality of life of Brazilian patients in palliative care: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 PAL (EORTC QLQ-C15-PAL). Support Care Cancer 2014; 22:1595.</a></li><li class="breakAll">FACIT group. Available at: www.facit.org (Accessed on February 12, 2021).</li><li><a class="nounderline abstract_t">Ahmad FS, Kallen MA, Schifferdecker KE, et al. Development and Initial Validation of the PROMIS®-Plus-HF Profile Measure. Circ Heart Fail 2019; 12:e005751.</a></li><li><a class="nounderline abstract_t">Schifferdecker KE, Yount SE, Kaiser K, et al. A method to create a standardized generic and condition-specific patient-reported outcome measure for patient care and healthcare improvement. Qual Life Res 2018; 27:367.</a></li><li><a class="nounderline abstract_t">Keller S, Yang M, Treadwell MJ, Hassell KL. Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS® to ASCQ-Me℠. Health Qual Life Outcomes 2017; 15:117.</a></li><li><a class="nounderline abstract_t">Rothrock NE, Hays RD, Spritzer K, et al. Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol 2010; 63:1195.</a></li><li><a class="nounderline abstract_t">Cook KF, Jensen SE, Schalet BD, et al. PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions. J Clin Epidemiol 2016; 73:89.</a></li><li><a class="nounderline abstract_t">Forrest CB, Bevans KB, Tucker C, et al. Commentary: the patient-reported outcome measurement information system (PROMIS®) for children and youth: application to pediatric psychology. J Pediatr Psychol 2012; 37:614.</a></li><li><a class="nounderline abstract_t">Blackwell CK, Wakschlag L, Krogh-Jespersen S, et al. Pragmatic Health Assessment in Early Childhood: The PROMIS® of Developmentally Based Measurement for Pediatric Psychology. J Pediatr Psychol 2020; 45:311.</a></li><li><a class="nounderline abstract_t">DeWalt DA, Rothrock N, Yount S, et al. Evaluation of item candidates: the PROMIS qualitative item review. Med Care 2007; 45:S12.</a></li><li><a class="nounderline abstract_t">Irwin DE, Varni JW, Yeatts K, DeWalt DA. Cognitive interviewing methodology in the development of a pediatric item bank: a patient reported outcomes measurement information system (PROMIS) study. Health Qual Life Outcomes 2009; 7:3.</a></li><li><a class="nounderline abstract_t">Bevans KB, Gardner W, Pajer K, et al. Qualitative development of the PROMIS(R) pediatric stress response item banks. J Pediatr Psychol 2013; 38:173.</a></li><li><a class="nounderline abstract_t">Reeve BB, Hays RD, Bjorner JB, et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care 2007; 45:S22.</a></li><li><a class="nounderline abstract_t">Revicki DA, Chen WH, Harnam N, et al. Development and psychometric analysis of the PROMIS pain behavior item bank. Pain 2009; 146:158.</a></li><li><a class="nounderline abstract_t">Hong I, Velozo CA, Li CY, et al. Assessment of the psychometrics of a PROMIS item bank: self-efficacy for managing daily activities. Qual Life Res 2016; 25:2221.</a></li><li><a class="nounderline abstract_t">Cella D, Gershon R, Lai JS, Choi S. The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. Qual Life Res 2007; 16 Suppl 1:133.</a></li><li><a class="nounderline abstract_t">Dionne-Odom JN, Ejem DB, Wells R, et al. Effects of a Telehealth Early Palliative Care Intervention for Family Caregivers of Persons With Advanced Heart Failure: The ENABLE CHF-PC Randomized Clinical Trial. JAMA Netw Open 2020; 3:e202583.</a></li><li><a class="nounderline abstract_t">Downing NR, Goodnight S, Chae S, et al. Factors Associated With End-of-Life Planning in Huntington Disease. Am J Hosp Palliat Care 2018; 35:440.</a></li><li><a class="nounderline abstract_t">Holden SK, Koljack CE, Prizer LP, et al. Measuring quality of life in palliative care for Parkinson's disease: A clinimetric comparison. Parkinsonism Relat Disord 2019; 65:172.</a></li><li><a class="nounderline abstract_t">Wells R, Ejem D, Dionne-Odom JN, et al. Protocol driven palliative care consultation: Outcomes of the ENABLE CHF-PC pilot study. Heart Lung 2018; 47:533.</a></li><li><a class="nounderline abstract_t">Stukenborg GJ, Blackhall LJ, Harrison JH, et al. Longitudinal patterns of cancer patient reported outcomes in end of life care predict survival. Support Care Cancer 2016; 24:2217.</a></li><li><a class="nounderline abstract_t">Cella D, Nowinski C, Peterman A, et al. The neurology quality-of-life measurement initiative. Arch Phys Med Rehabil 2011; 92:S28.</a></li><li><a class="nounderline abstract_t">Gershon RC, Lai JS, Bode R, et al. Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res 2012; 21:475.</a></li><li><a class="nounderline abstract_t">Lai JS, Nowinski C, Victorson D, et al. Quality-of-life measures in children with neurological conditions: pediatric Neuro-QOL. Neurorehabil Neural Repair 2012; 26:36.</a></li><li><a class="nounderline abstract_t">Tulsky DS, Kisala PA, Victorson D, et al. Overview of the Spinal Cord Injury--Quality of Life (SCI-QOL) measurement system. J Spinal Cord Med 2015; 38:257.</a></li><li><a class="nounderline abstract_t">Tulsky DS, Kisala PA, Victorson D, et al. TBI-QOL: Development and Calibration of Item Banks to Measure Patient Reported Outcomes Following Traumatic Brain Injury. J Head Trauma Rehabil 2016; 31:40.</a></li><li><a class="nounderline abstract_t">Carlozzi NE, Schilling SG, Lai JS, et al. HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Qual Life Res 2016; 25:2441.</a></li><li><a class="nounderline abstract_t">Carlozzi NE, Kallen MA, Hanks R, et al. The TBI-CareQOL Measurement System: Development and Preliminary Validation of Health-Related Quality of Life Measures for Caregivers of Civilians and Service Members/Veterans With Traumatic Brain Injury. Arch Phys Med Rehabil 2019; 100:S1.</a></li><li><a class="nounderline abstract_t">Katzan IL, Thompson N, Uchino K. Innovations in Stroke: The Use of PROMIS and NeuroQoL Scales in Clinical Stroke Trials. Stroke 2016; 47:e27.</a></li><li><a class="nounderline abstract_t">Gauthier LV, Kane C, Borstad A, et al. Video Game Rehabilitation for Outpatient Stroke (VIGoROUS): protocol for a multi-center comparative effectiveness trial of in-home gamified constraint-induced movement therapy for rehabilitation of chronic upper extremity hemiparesis. BMC Neurol 2017; 17:109.</a></li><li><a class="nounderline abstract_t">Arlt S, Hornung J, Eichenlaub M, et al. The patient with dementia, the caregiver and the doctor: cognition, depression and quality of life from three perspectives. Int J Geriatr Psychiatry 2008; 23:604.</a></li><li><a class="nounderline abstract_t">Gundy CM, Aaronson NK. The influence of proxy perspective on patient-proxy agreement in the evaluation of health-related quality of life: an empirical study. Med Care 2008; 46:209.</a></li><li><a class="nounderline abstract_t">Klaassen RJ, Barr RD, Hughes J, et al. Nurses provide valuable proxy assessment of the health-related quality of life of children with Hodgkin disease. Cancer 2010; 116:1602.</a></li><li><a class="nounderline abstract_t">McGrath C, McMillan AS, Zhu HW, Li LS. Agreement between patient and proxy assessments of oral health-related quality of life after stroke: an observational longitudinal study. J Oral Rehabil 2009; 36:264.</a></li><li><a class="nounderline abstract_t">McPhail S, Beller E, Haines T. Two perspectives of proxy reporting of health-related quality of life using the Euroqol-5D, an investigation of agreement. Med Care 2008; 46:1140.</a></li><li><a class="nounderline abstract_t">Hocaoglu MB, Gaffan EA, Ho AK. Health-related quality of life in Huntington's disease patients: a comparison of proxy assessment and patient self-rating using the disease-specific Huntington's disease health-related quality of life questionnaire (HDQoL). J Neurol 2012; 259:1793.</a></li><li><a class="nounderline abstract_t">Jones JM, McPherson CJ, Zimmermann C, et al. Assessing agreement between terminally ill cancer patients' reports of their quality of life and family caregiver and palliative care physician proxy ratings. J Pain Symptom Manage 2011; 42:354.</a></li><li><a class="nounderline abstract_t">Karlawish JH, Zbrozek A, Kinosian B, et al. Caregivers' assessments of preference-based quality of life in Alzheimer's disease. Alzheimers Dement 2008; 4:203.</a></li><li><a class="nounderline abstract_t">Radina ME. Toward a Theory of Health-Related Family Quality of Life. J Fam Theory Rev 2013; 5:35.</a></li><li><a class="nounderline abstract_t">Golics CJ, Basra MK, Finlay AY, Salek S. The impact of disease on family members: a critical aspect of medical care. J R Soc Med 2013; 106:399.</a></li><li><a class="nounderline abstract_t">Cheung YB, Goh C, Thumboo J, et al. Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires. J Clin Oncol 2005; 23:4936.</a></li><li><a class="nounderline abstract_t">Jensen RE, Rothrock NE, DeWitt EM, et al. The role of technical advances in the adoption and integration of patient-reported outcomes in clinical care. Med Care 2015; 53:153.</a></li><li><a class="nounderline abstract_t">Lavallee DC, Chenok KE, Love RM, et al. Incorporating Patient-Reported Outcomes Into Health Care To Engage Patients And Enhance Care. Health Aff (Millwood) 2016; 35:575.</a></li><li><a class="nounderline abstract_t">Chen J, Ou L, Hollis SJ. A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res 2013; 13:211.</a></li><li><a class="nounderline abstract_t">Etkind SN, Daveson BA, Kwok W, et al. Capture, transfer, and feedback of patient-centered outcomes data in palliative care populations: does it make a difference? A systematic review. J Pain Symptom Manage 2015; 49:611.</a></li><li><a class="nounderline abstract_t">Howell D, Molloy S, Wilkinson K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol 2015; 26:1846.</a></li><li><a class="nounderline abstract_t">Denis F, Basch E, Septans AL, et al. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. JAMA 2019; 321:306.</a></li><li><a class="nounderline abstract_t">Ishaque S, Karnon J, Chen G, et al. A systematic review of randomised controlled trials evaluating the use of patient-reported outcome measures (PROMs). Qual Life Res 2019; 28:567.</a></li><li><a class="nounderline abstract_t">Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol 2016; 34:557.</a></li><li><a class="nounderline abstract_t">Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA 2002; 288:3027.</a></li><li><a class="nounderline abstract_t">Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 2004; 22:714.</a></li><li><a class="nounderline abstract_t">Wagner LI, Spiegel D, Pearman T. Using the science of psychosocial care to implement the new american college of surgeons commission on cancer distress screening standard. J Natl Compr Canc Netw 2013; 11:214.</a></li><li><a class="nounderline abstract_t">Gibbons C, Porter I, Gonçalves-Bradley DC, et al. Routine provision of feedback from patient-reported outcome measurements to healthcare providers and patients in clinical practice. Cochrane Database Syst Rev 2021; 10:CD011589.</a></li><li><a class="nounderline abstract_t">Garcia SF, Smith JD, Kallen M, et al. Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre. BMJ Open 2022; 12:e059563.</a></li><li><a class="nounderline abstract_t">Basch E, Schrag D, Henson S, et al. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. JAMA 2022; 327:2413.</a></li><li><a class="nounderline abstract_t">Broderick JE, DeWitt ME, Rothrock N, et al. Advances in patient reported outcomes: The NIH PROMIS measures. eGEMs 2013; 1.</a></li><li><a class="nounderline abstract_t">Baumhauer JF, Bozic KJ. Value-based Healthcare: Patient-reported Outcomes in Clinical Decision Making. Clin Orthop Relat Res 2016; 474:1375.</a></li><li><a class="nounderline abstract_t">Perry LM, Morken V, Peipert JD, et al. Patient-Reported Outcome Dashboards Within the Electronic Health Record to Support Shared Decision-making: Protocol for Co-design and Clinical Evaluation With Patients With Advanced Cancer and Chronic Kidney Disease. JMIR Res Protoc 2022; 11:e38461.</a></li><li><a class="nounderline abstract_t">Antunes B, Harding R, Higginson IJ, EUROIMPACT. Implementing patient-reported outcome measures in palliative care clinical practice: a systematic review of facilitators and barriers. Palliat Med 2014; 28:158.</a></li><li><a class="nounderline abstract_t">Eilayyan O, Visca R, Zidarov D, et al. Developing theory-informed knowledge translation strategies to facilitate the use of patient-reported outcome measures in interdisciplinary low back pain clinical practices in Quebec: mixed methods study. BMC Health Serv Res 2020; 20:789.</a></li><li><a class="nounderline abstract_t">Sisodia RC, Dewdney SB, Fader AN, et al. Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I. Gynecol Oncol 2020; 158:194.</a></li><li><a class="nounderline abstract_t">Gerhardt WE, Mara CA, Kudel I, et al. Systemwide Implementation of Patient-Reported Outcomes in Routine Clinical Care at a Children's Hospital. Jt Comm J Qual Patient Saf 2018; 44:441.</a></li><li><a class="nounderline abstract_t">Biber J, Ose D, Reese J, et al. Patient reported outcomes - experiences with implementation in a University Health Care setting. J Patient Rep Outcomes 2017; 2:34.</a></li><li><a class="nounderline abstract_t">Nelson TA, Anderson B, Bian J, et al. Planning for patient-reported outcome implementation: Development of decision tools and practical experience across four clinics. J Clin Transl Sci 2020; 4:498.</a></li><li><a class="nounderline abstract_t">Foster A, Croot L, Brazier J, et al. The facilitators and barriers to implementing patient reported outcome measures in organisations delivering health related services: a systematic review of reviews. J Patient Rep Outcomes 2018; 2:46.</a></li><li><a class="nounderline abstract_t">Chan EKH, Edwards TC, Haywood K, et al. Implementing patient-reported outcome measures in clinical practice: a companion guide to the ISOQOL user's guide. Qual Life Res 2019; 28:621.</a></li><li class="breakAll">National Quality Forum. Patient-reported outcomes: Best practices on selection and data collection. 2020. Available at: http://www.qualityforum.org/Publications/2020/09/Patient-Reported_Outcomes__Best_Practices_on_Selection_and_Data_Collection_-_Final_Technical_Report.aspx (Accessed on February 12, 2021).</li><li class="breakAll">LeRouge C, Austen E, Lee J, et al. ePROs in Clinical Care: Guidelines and tools for
health systems. CERTAIN 2020. Available at: http://epros.becertain.org/sites/epros.becertain.org/files/tools/ePROs%20in%20clinical%20care%20print%20edition%20%28v1.1%29%20.pdf (Accessed on February 12, 2021).</li><li><a class="nounderline abstract_t">Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18:623.</a></li><li><a class="nounderline abstract_t">Eton DT, Fairclough DL, Cella D, et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 2003; 21:1536.</a></li><li><a class="nounderline abstract_t">Gotay CC. Trial-related quality of life: using quality-of-life assessment to distinguish among cancer therapies. J Natl Cancer Inst Monogr 1996; :1.</a></li><li><a class="nounderline abstract_t">Franklin PD, Zheng H, Bond C, Lavallee DC. Translating clinical and patient-reported data to tailored shared decision reports with predictive analytics for knee and hip arthritis. Qual Life Res 2021; 30:3171.</a></li><li><a class="nounderline abstract_t">Yellen SB, Cella DF. Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 1995; 13:1255.</a></li><li><a class="nounderline abstract_t">Cicirelli VG. Relationship of psychosocial and background variables to older adults' end-of-life decisions. Psychol Aging 1997; 12:72.</a></li><li><a class="nounderline abstract_t">Abernethy AP, Aziz NM, Basch E, et al. A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group. J Palliat Med 2010; 13:1407.</a></li><li><a class="nounderline abstract_t">LeBlanc TW, Kutner JS, Ko D, et al. Developing the evidence base for palliative care: formation of the Palliative Care Research Cooperative and its first trial. Hosp Pract (1995) 2010; 38:137.</a></li><li class="breakAll">Abernethy AP, Kutner J, Blatchford PJ, et al. Managing comorbidities in oncology: a multisite randomized controlled trial of continuing versus discontinuing statins in the setting of life-limiting illness (abstract). J Clin Oncol 32:5s, 2014 (suppl; abstr LBA9514). Abstract available online at http://meetinglibrary.asco.org/content/135132-144 (Accessed on January 07, 2015).</li><li><a class="nounderline abstract_t">Bennett AV, Lee S, Drier S, et al. A Library of Instruments Endorsed by Published Systematic Reviews for Assessing Patients and Their Care Developed by the Palliative Care Research Cooperative. J Palliat Med 2017; 20:910.</a></li><li class="breakAll">Centers for Medicare &amp; Medicaid Services. CMS Measures Management System Blueprint (Blueprint v 14.1). https://www.cms.gov/medicare/quality-initiatives-patient-assessment-instruments/mms/mms-blueprint.html (Accessed on May 15, 2019).</li><li class="breakAll">Centers for Medicare and Medicaid Services. CMS Measures Management System Blueprint (Blueprint v16.0). Available at: https://www.cms.gov/medicare/quality-initiatives-patient-assessment-instruments/mms/mms-blueprint (Accessed on February 12, 2021).</li><li class="breakAll">Cella D, Hahn EA, Jensen SE, et al. Patient-reported outcomes in performance measurement, RTI Press, Research Triangle Park 2015.</li><li class="breakAll">National Quality Forum. Patient-Reported Outcome Measures to Patient-Reported Outcome Performance Measures - Technical Guidance Final Report. 2022. Available at: https://www.qualityforum.org/Publications/2022/11/Patient-Reported_Outcome_Measures_to_Patient-Reported_Outcome_Performance_Measures_-_Technical_Guidance_Final_Report.aspx (Accessed on April 24, 2023).</li><li class="breakAll">Burstin H, Cobb K, McQueston K, et al. Measuring what matters to patients: Innovations in integrating the patient experience into development of meaningful performance measures. National Quality Forum 2017. Available at: http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&amp;ItemID=85770 (Accessed on February 12, 2021).</li><li><a class="nounderline abstract_t">Buchanan DR, O'Mara AM, Kelaghan JW, et al. Challenges and recommendations for advancing the state-of-the-science of quality of life assessment in symptom management trials. Cancer 2007; 110:1621.</a></li><li><a class="nounderline abstract_t">Sprangers MA, Moinpour CM, Moynihan TJ, et al. Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clin Proc 2002; 77:561.</a></li><li><a class="nounderline abstract_t">Cella D, Bullinger M, Scott C, et al. Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin Proc 2002; 77:384.</a></li><li><a class="nounderline abstract_t">Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008; 61:102.</a></li><li><a class="nounderline abstract_t">McGraw S, Qian Y, Henne J, et al. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol 2017; 17:68.</a></li><li><a class="nounderline abstract_t">Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10:407.</a></li><li><a class="nounderline abstract_t">Yost KJ, Sorensen MV, Hahn EA, et al. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health 2005; 8:117.</a></li><li><a class="nounderline abstract_t">Funk GF, Karnell LH, Smith RB, Christensen AJ. Clinical significance of health status assessment measures in head and neck cancer: what do quality-of-life scores mean? Arch Otolaryngol Head Neck Surg 2004; 130:825.</a></li><li><a class="nounderline abstract_t">Gulbrandsen N, Hjermstad MJ, Wisløff F, Nordic Myeloma Study Group. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 2004; 72:172.</a></li><li><a class="nounderline abstract_t">Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41:582.</a></li><li><a class="nounderline abstract_t">Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof 2005; 28:172.</a></li><li><a class="nounderline abstract_t">Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol 2011; 64:507.</a></li><li><a class="nounderline abstract_t">Cook KF, Cella D, Reeve BB. PRO-Bookmarking to Estimate Clinical Thresholds for Patient-reported Symptoms and Function. Med Care 2019; 57 Suppl 5 Suppl 1:S13.</a></li><li><a class="nounderline abstract_t">Cella D, Choi S, Garcia S, et al. Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment. Qual Life Res 2014; 23:2651.</a></li><li><a class="nounderline abstract_t">Rothrock NE, Cook KF, O'Connor M, et al. Establishing clinically-relevant terms and severity thresholds for Patient-Reported Outcomes Measurement Information System® (PROMIS®) measures of physical function, cognitive function, and sleep disturbance in people with cancer using standard setting. Qual Life Res 2019; 28:3355.</a></li><li><a class="nounderline abstract_t">Cook KF, Victorson DE, Cella D, et al. Creating meaningful cut-scores for Neuro-QOL measures of fatigue, physical functioning, and sleep disturbance using standard setting with patients and providers. Qual Life Res 2015; 24:575.</a></li><li><a class="nounderline abstract_t">Nagaraja V, Mara C, Khanna PP, et al. Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases. Qual Life Res 2018; 27:755.</a></li><li><a class="nounderline abstract_t">Bingham CO, Butanis AL, Orbai AM, et al. Patients and clinicians define symptom levels and meaningful change for PROMIS pain interference and fatigue in RA using bookmarking. Rheumatology (Oxford) 2021; 60:4306.</a></li><li><a class="nounderline abstract_t">Kisala PA, Victorson D, Nandakumar R, et al. Applying a Bookmarking Approach to Setting Clinically Relevant Interpretive Standards for the Spinal Cord Injury-Functional Index/Capacity Basic Mobility and Self-Care Item Bank Scores. Arch Phys Med Rehabil 2022; 103:224.</a></li><li><a class="nounderline abstract_t">Morgan EM, Mara CA, Huang B, et al. Establishing clinical meaning and defining important differences for Patient-Reported Outcomes Measurement Information System (PROMIS®) measures in juvenile idiopathic arthritis using standard setting with patients, parents, and providers. Qual Life Res 2017; 26:565.</a></li><li><a class="nounderline abstract_t">Olsen MF, Bjerre E, Hansen MD, et al. Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain. BMC Med 2017; 15:35.</a></li><li><a class="nounderline abstract_t">Coon CD, Cook KF. Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores. Qual Life Res 2018; 27:33.</a></li><li><a class="nounderline abstract_t">Mularski RA, Rosenfeld K, Coons SJ, et al. Measuring outcomes in randomized prospective trials in palliative care. J Pain Symptom Manage 2007; 34:S7.</a></li><li><a class="nounderline abstract_t">Robbins RA, Simmons Z, Bremer BA, et al. Quality of life in ALS is maintained as physical function declines. Neurology 2001; 56:442.</a></li><li><a class="nounderline abstract_t">Brady MJ, Peterman AH, Fitchett G, et al. A case for including spirituality in quality of life measurement in oncology. Psychooncology 1999; 8:417.</a></li><li><a class="nounderline abstract_t">Peterman AH, Fitchett G, Brady MJ, et al. Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med 2002; 24:49.</a></li><li><a class="nounderline abstract_t">Khan L, Zeng L, Cella D, et al. Patients' and Health Care Providers' Evaluation of Quality of Life Issues in Advanced Cancer Using Functional Assessment of Chronic Illness Therapy - Palliative Care Module (FACIT-Pal) Scale. World J Oncol 2012; 3:210.</a></li><li><a class="nounderline abstract_t">Steinhauser KE, Bosworth HB, Clipp EC, et al. Initial assessment of a new instrument to measure quality of life at the end of life. J Palliat Med 2002; 5:829.</a></li><li><a class="nounderline abstract_t">Philip EJ, Merluzzi TV, Peterman A, Cronk LB. Measurement accuracy in assessing patient's quality of life: to weight or not to weight domains of quality of life. Qual Life Res 2009; 18:775.</a></li><li><a class="nounderline abstract_t">Ruta DA, Garratt AM, Leng M, et al. A new approach to the measurement of quality of life. The Patient-Generated Index. Med Care 1994; 32:1109.</a></li><li><a class="nounderline abstract_t">Hickey AM, Bury G, O'Boyle CA, et al. A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV/AIDS. BMJ 1996; 313:29.</a></li><li><a class="nounderline abstract_t">Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995; 273:59.</a></li><li><a class="nounderline abstract_t">Cohen SR, Mount BM, Strobel MG, Bui F. The McGill Quality of Life Questionnaire: a measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med 1995; 9:207.</a></li><li><a class="nounderline abstract_t">Cohen SR, Sawatzky R, Russell LB, et al. Measuring the quality of life of people at the end of life: The McGill Quality of Life Questionnaire-Revised. Palliat Med 2017; 31:120.</a></li><li><a class="nounderline abstract_t">Breitbart W, Rosenfeld B, Pessin H, et al. Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer. J Clin Oncol 2015; 33:749.</a></li><li class="breakAll">Breitbart WS, Poppito S. Individual Meaning-Centered Psychotherapy for People with Advanced Cancer: A Treatment Manual, Oxford University Press, New York 2018.</li><li><a class="nounderline abstract_t">Gründer G, Heinze M, Cordes J, et al. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry 2016; 3:717.</a></li><li><a class="nounderline abstract_t">Kane JM, Robinson DG, Schooler NR, et al. Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. Am J Psychiatry 2016; 173:362.</a></li><li><a class="nounderline abstract_t">Kamenov K, Twomey C, Cabello M, et al. The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis. Psychol Med 2017; 47:414.</a></li><li><a class="nounderline abstract_t">Güney P, Ekman CJ, Hammar Å, et al. Electroconvulsive Therapy in Depression: Improvement in Quality of Life Depending on Age and Sex. J ECT 2020; 36:242.</a></li><li><a class="nounderline abstract_t">Morton E, Murray G, Michalak EE, et al. Quality of life in bipolar disorder: towards a dynamic understanding. Psychol Med 2018; 48:1111.</a></li><li><a class="nounderline abstract_t">Schnurr PP, Lunney CA. SYMPTOM BENCHMARKS OF IMPROVED QUALITY OF LIFE IN PTSD. Depress Anxiety 2016; 33:247.</a></li><li><a class="nounderline abstract_t">Lambert MJ, Whipple JL, Kleinstäuber M. Collecting and delivering progress feedback: A meta-analysis of routine outcome monitoring. Psychotherapy (Chic) 2018; 55:520.</a></li><li><a class="nounderline abstract_t">Wampold BE. Routine outcome monitoring: Coming of age--With the usual developmental challenges. Psychotherapy (Chic) 2015; 52:458.</a></li><li><a class="nounderline abstract_t">McAleavey AA, Moltu C. Understanding routine outcome monitoring and clinical feedback in context: Introduction to the special section. Psychother Res 2021; 31:142.</a></li><li><a class="nounderline abstract_t">Priebe S, Reininghaus U, McCabe R, et al. Factors influencing subjective quality of life in patients with schizophrenia and other mental disorders: a pooled analysis. Schizophr Res 2010; 121:251.</a></li><li class="breakAll">Sirgy MJ. The Psychology of Quality of Life: Hedonic Well-Being, Life Satisfaction, and Eudaimonia, 2nd ed, Springer, Netherlands 2012.</li><li><a class="nounderline abstract_t">Ritsner MS, Arbitman M, Lisker A, Ponizovsky AM. Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors. Qual Life Res 2012; 21:1075.</a></li></ol></div><div id="topicVersionRevision">Topic 2833 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2646487" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Quality of life, health status, and clinical research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4042094" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Food and Drug Administration requirements for approval of new anticancer drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4042094" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Food and Drug Administration requirements for approval of new anticancer drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26758559" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35990594" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A Patient Reported Outcome Ontology: Conceptual Issues and Challenges Addressed by the Patient-Reported Outcomes Measurement Information System®(PROMIS®).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35990594" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A Patient Reported Outcome Ontology: Conceptual Issues and Challenges Addressed by the Patient-Reported Outcomes Measurement Information System®(PROMIS®).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6699671" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Karnofsky performance status revisited: reliability, validity, and guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17951232" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Re-personalizing precision medicine: Is there a role for patient-reported outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30658932" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30178193" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30213449" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35759733" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35489363" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24756142" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Patient-reported outcome performance measures in oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7537908" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Measuring quality of life in palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3079329" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Quality of life: what is it? How should it be measured?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8596551" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Assessment of quality-of-life outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19758610" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Differing perceptions of quality of life in patients with prostate cancer and their doctors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443116" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20685078" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35552430" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bringing PROMIS to Early Childhood: Introduction and Qualitative Methods for the Development of Early Childhood Parent Report Instruments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8827649" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Posttraumatic Growth Inventory: measuring the positive legacy of trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20192563" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Making sense of the meaning literature: an integrative review of meaning making and its effects on adjustment to stressful life events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21643875" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The psychosocial impact of cancer: evidence in support of independent general positive and negative components.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549841" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cancer symptom assessment instruments: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3989783" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Measuring health status: a new tool for clinicians and epidemiologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1593914" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19509357" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Impact of cancer on health-related quality of life of older Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2646490" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Generic and disease-specific measures in assessing health status and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7278416" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The Sickness Impact Profile: development and final revision of a health status measure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7278416" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Sickness Impact Profile: development and final revision of a health status measure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3066604" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). The DCCT Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6374052" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24922521" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparison of three shortened questionnaires for assessment of quality of life in advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23136235" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The FACT-G7: a rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162404" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24463615" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The quality of life of Brazilian patients in palliative care: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 PAL (EORTC QLQ-C15-PAL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24463615" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The quality of life of Brazilian patients in palliative care: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 PAL (EORTC QLQ-C15-PAL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31163985" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Development and Initial Validation of the PROMIS®-Plus-HF Profile Measure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28795261" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A method to create a standardized generic and condition-specific patient-reported outcome measure for patient care and healthcare improvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28577358" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS®to ASCQ-Me℠.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20688471" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26952842" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22362923" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Commentary: the patient-reported outcome measurement information system (PROMIS®) for children and youth: application to pediatric psychology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31774488" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pragmatic Health Assessment in Early Childhood: The PROMIS®of Developmentally Based Measurement for Pediatric Psychology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443114" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Evaluation of item candidates: the PROMIS qualitative item review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19166601" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cognitive interviewing methodology in the development of a pediatric item bank: a patient reported outcomes measurement information system (PROMIS) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23124904" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Qualitative development of the PROMIS(R) pediatric stress response item banks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443115" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19683873" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Development and psychometric analysis of the PROMIS pain behavior item bank.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27048495" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Assessment of the psychometrics of a PROMIS item bank: self-efficacy for managing daily activities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401637" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32282044" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effects of a Telehealth Early Palliative Care Intervention for Family Caregivers of Persons With Advanced Heart Failure: The ENABLE CHF-PC Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28655280" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Factors Associated With End-of-Life Planning in Huntington Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31253494" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Measuring quality of life in palliative care for Parkinson's disease: A clinimetric comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30143363" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Protocol driven palliative care consultation: Outcomes of the ENABLE CHF-PC pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26573279" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Longitudinal patterns of cancer patient reported outcomes in end of life care predict survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21958920" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The neurology quality-of-life measurement initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21874314" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21788436" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Quality-of-life measures in children with neurological conditions: pediatric Neuro-QOL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26010962" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Overview of the Spinal Cord Injury--Quality of Life (SCI-QOL) measurement system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25931184" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : TBI-QOL: Development and Calibration of Item Banks to Measure Patient Reported Outcomes Following Traumatic Brain Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27522213" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30195987" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The TBI-CareQOL Measurement System: Development and Preliminary Validation of Health-Related Quality of Life Measures for Caregivers of Civilians and Service Members/Veterans With Traumatic Brain Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26732572" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Innovations in Stroke: The Use of PROMIS and NeuroQoL Scales in Clinical Stroke Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28595611" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Video Game Rehabilitation for Outpatient Stroke (VIGoROUS): protocol for a multi-center comparative effectiveness trial of in-home gamified constraint-induced movement therapy for rehabilitation of chronic upper extremity hemiparesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18008392" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The patient with dementia, the caregiver and the doctor: cognition, depression and quality of life from three perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18219250" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The influence of proxy perspective on patient-proxy agreement in the evaluation of health-related quality of life: an empirical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20131350" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Nurses provide valuable proxy assessment of the health-related quality of life of children with Hodgkin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19220712" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Agreement between patient and proxy assessments of oral health-related quality of life after stroke: an observational longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18953224" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Two perspectives of proxy reporting of health-related quality of life using the Euroqol-5D, an investigation of agreement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22392579" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Health-related quality of life in Huntington's disease patients: a comparison of proxy assessment and patient self-rating using the disease-specific Huntington's disease health-related quality of life questionnaire (HDQoL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21454041" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Assessing agreement between terminally ill cancer patients' reports of their quality of life and family caregiver and palliative care physician proxy ratings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18631969" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Caregivers' assessments of preference-based quality of life in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Toward a Theory of Health-Related Family Quality of Life</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23759884" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The impact of disease on family members: a critical aspect of medical care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16051946" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25588135" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The role of technical advances in the adoption and integration of patient-reported outcomes in clinical care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27044954" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Incorporating Patient-Reported Outcomes Into Health Care To Engage Patients And Enhance Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23758898" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25135657" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Capture, transfer, and feedback of patient-centered outcomes data in palliative care populations: does it make a difference? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25888610" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30667494" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30284183" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A systematic review of randomised controlled trials evaluating the use of patient-reported outcome measures (PROMs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26644527" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12479768" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14966096" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23411387" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Using the science of psychosocial care to implement the new american college of surgeons commission on cancer distress screening standard.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34637526" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Routine provision of feedback from patient-reported outcome measurements to healthcare providers and patients in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35504641" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35661856" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Advances in patient reported outcomes: The NIH PROMIS measures</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27052020" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Value-based Healthcare: Patient-reported Outcomes in Clinical Decision Making.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36129747" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Patient-Reported Outcome Dashboards Within the Electronic Health Record to Support Shared Decision-making: Protocol for Co-design and Clinical Evaluation With Patients With Advanced Cancer and Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23801463" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Implementing patient-reported outcome measures in palliative care clinical practice: a systematic review of facilitators and barriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32843032" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Developing theory-informed knowledge translation strategies to facilitate the use of patient-reported outcome measures in interdisciplinary low back pain clinical practices in Quebec: mixed methods study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32580886" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30071964" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Systemwide Implementation of Patient-Reported Outcomes in Routine Clinical Care at a Children's Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30175316" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Patient reported outcomes - experiences with implementation in a University Health Care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33948226" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Planning for patient-reported outcome implementation: Development of decision tools and practical experience across four clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30363333" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The facilitators and barriers to implementing patient reported outcome measures in organisations delivering health related services: a systematic review of reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30448911" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Implementing patient-reported outcome measures in clinical practice: a companion guide to the ISOQOL user's guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30448911" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Implementing patient-reported outcome measures in clinical practice: a companion guide to the ISOQOL user's guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30448911" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Implementing patient-reported outcome measures in clinical practice: a companion guide to the ISOQOL user's guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10653877" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12697878" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8750459" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Trial-related quality of life: using quality-of-life assessment to distinguish among cancer therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32562194" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Translating clinical and patient-reported data to tailored shared decision reports with predictive analytics for knee and hip arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7738630" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Someone to live for: social well-being, parenthood status, and decision-making in oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9100269" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Relationship of psychosocial and background variables to older adults' end-of-life decisions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21105763" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20890063" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Developing the evidence base for palliative care: formation of the Palliative Care Research Cooperative and its first trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20890063" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Developing the evidence base for palliative care: formation of the Palliative Care Research Cooperative and its first trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28541835" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : A Library of Instruments Endorsed by Published Systematic Reviews for Assessing Patients and Their Care Developed by the Palliative Care Research Cooperative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28541835" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : A Library of Instruments Endorsed by Published Systematic Reviews for Assessing Patients and Their Care Developed by the Palliative Care Research Cooperative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28541835" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : A Library of Instruments Endorsed by Published Systematic Reviews for Assessing Patients and Their Care Developed by the Palliative Care Research Cooperative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28541835" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : A Library of Instruments Endorsed by Published Systematic Reviews for Assessing Patients and Their Care Developed by the Palliative Care Research Cooperative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28541835" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : A Library of Instruments Endorsed by Published Systematic Reviews for Assessing Patients and Their Care Developed by the Palliative Care Research Cooperative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28541835" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : A Library of Instruments Endorsed by Published Systematic Reviews for Assessing Patients and Their Care Developed by the Palliative Care Research Cooperative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868120" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Challenges and recommendations for advancing the state-of-the-science of quality of life assessment in symptom management trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12059127" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Assessing meaningful change in quality of life over time: a users' guide for clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11936936" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18177782" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28376816" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : A qualitative study of perceptions of meaningful change in spinal muscular atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2691207" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Measurement of health status. Ascertaining the minimal clinically important difference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15804320" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15262758" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Clinical significance of health status assessment measures in head and neck cancer: what do quality-of-life scores mean?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14962235" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12719681" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15851772" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21447427" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30985591" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : PRO-Bookmarking to Estimate Clinical Thresholds for Patient-reported Symptoms and Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24938431" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31410640" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Establishing clinically-relevant terms and severity thresholds for Patient-Reported Outcomes Measurement Information System®(PROMIS®) measures of physical function, cognitive function, and sleep disturbance in people with cancer using standard setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25148759" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Creating meaningful cut-scores for Neuro-QOL measures of fatigue, physical functioning, and sleep disturbance using standard setting with patients and providers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28983738" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Establishing clinical severity for PROMIS®measures in adult patients with rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33471127" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Patients and clinicians define symptom levels and meaningful change for PROMIS pain interference and fatigue in RA using bookmarking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33245941" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Applying a Bookmarking Approach to Setting Clinically Relevant Interpretive Standards for the Spinal Cord Injury-Functional Index/Capacity Basic Mobility and Self-Care Item Bank Scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27913986" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Establishing clinical meaning and defining important differences for Patient-Reported Outcomes Measurement Information System (PROMIS®) measures in juvenile idiopathic arthritis using standard setting with patients, parents, and providers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28215182" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28620874" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17532180" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Measuring outcomes in randomized prospective trials in palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11222784" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Quality of life in ALS is maintained as physical function declines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10559801" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : A case for including spirituality in quality of life measurement in oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12008794" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29147308" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Patients' and Health Care Providers' Evaluation of Quality of Life Issues in Advanced Cancer Using Functional Assessment of Chronic Illness Therapy - Palliative Care Module (FACIT-Pal) Scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12685529" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Initial assessment of a new instrument to measure quality of life at the end of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19496020" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Measurement accuracy in assessing patient's quality of life: to weight or not to weight domains of quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7967852" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : A new approach to the measurement of quality of life. The Patient-Generated Index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8664768" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV/AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7996652" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7582177" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : The McGill Quality of Life Questionnaire: a measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27412257" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Measuring the quality of life of people at the end of life: The McGill Quality of Life Questionnaire-Revised.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25646186" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25646186" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265548" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26481174" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27780478" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32108666" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Electroconvulsive Therapy in Depression: Improvement in Quality of Life Depending on Age and Sex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28918761" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Quality of life in bipolar disorder: towards a dynamic understanding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26882293" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : SYMPTOM BENCHMARKS OF IMPROVED QUALITY OF LIFE IN PTSD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30335463" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Collecting and delivering progress feedback: A meta-analysis of routine outcome monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26641376" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Routine outcome monitoring: Coming of age--With the usual developmental challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33522465" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Understanding routine outcome monitoring and clinical feedback in context: Introduction to the special section.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20483566" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Factors influencing subjective quality of life in patients with schizophrenia and other mental disorders: a pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20483566" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Factors influencing subjective quality of life in patients with schizophrenia and other mental disorders: a pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21964946" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
